Aminoglycoside suppression of nonsense mutations in severe hemophilia

Aminoglycoside antibiotics exhibit their bactericidal effect by interfering with normal ribosomal activity. In this pilot study, we have evaluated the effect of the aminoglycoside antibiotic gentamicin on the factor VIII (FVIII) and IX levels of severe hemophiliacs with known nonsense mutations. Fiv...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2005-11, Vol.106 (9), p.3043-3048
Main Authors: James, Paula D., Raut, Sanj, Rivard, Georges E., Poon, Man-Chiu, Warner, Margaret, McKenna, Susan, Leggo, Jayne, Lillicrap, David
Format: Article
Language:English
Subjects:
Aminoglycosides - pharmacology
Biological and medical sciences
Codon, Nonsense - genetics
Factor IX - metabolism
Factor VIII - metabolism
Gentamicins - pharmacology
Hematologic and hematopoietic diseases
Hemophilia A - genetics
Humans
Medical sciences
Partial Thromboplastin Time
Platelet diseases and coagulopathies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aminoglycoside antibiotics exhibit their bactericidal effect by interfering with normal ribosomal activity. In this pilot study, we have evaluated the effect of the aminoglycoside antibiotic gentamicin on the factor VIII (FVIII) and IX levels of severe hemophiliacs with known nonsense mutations. Five patients were enrolled and each patient was given 3 consecutive days of gentamicin at a dose of 7 mg/kg intravenously every 24 hours. Two patients (patient no. 1: hemophilia A, Ser1395Stop; and patient no. 5: hemophilia B, Arg333Stop) showed a decrease in their activated partial thromboplastin time (aPTT), an increase in their FVIII (0.016 IU/mL, 1.6%) or FIX (0.02 IU/mL, 2%) levels, and an increase in thrombin generation. The remaining 3 patients (patient no. 2: hemophilia B, Arg252Stop; patient no. 3: hemophilia A, Arg2116Stop; and patient no. 4: hemophilia A, Arg427Stop) showed no response in the aPTTs or factor levels, but one (patient no. 2: hemophilia B, Arg252Stop) showed an increase in the factor IX antigen level (2%-5.5%) that persisted throughout the period of the study and was concordant with an increase in thrombin generation. Gentamicin is unlikely to be an effective treatment for severe hemophilia due to its potential toxicities and the minimal response documented in this report. This study, however, does provide a proof of principle, suggesting that ribosomal interference with a less toxic agent may be a potential therapeutic mechanism for severe hemophilia patients with nonsense mutations.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2005-03-1307